Psychosis News and Research

RSS

Psychosis means abnormal condition of the mind, and is a generic psychiatric term for a mental state often described as involving a "loss of contact with reality". People suffering from psychosis are said to be ''psychotic.''

Cannabis use accelerates psychosis in the young: Study

A new study has shown that cannabis use can hasten the onset of schizophrenia by several years. The study included data from 20,000 patients with a psychotic illness and found those who smoked cannabis were diagnosed almost three years ahead of those who did not use the drug. The research is published in the journal Archives of General Psychiatry.

8 Feb 2011

Schizophrenia patients who consume antipsychotics appear to lose small amount of brain tissue

Patients with schizophrenia who take antipsychotic medications appear to lose a small but measurable amount of brain tissue over time, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Feb 2011

Study: Cannabis use appears to be linked with earlier onset of psychotic illness

Cannabis use appears to be associated with an earlier onset of psychotic illness, according to a meta-analysis of previously published studies posted online today that will appear in the June print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Feb 2011

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Targacept, Inc. today announced positive top-line results from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia.

20 Jan 2011

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

Biological Psychiatry is proud to announce this week's publication of a special issue focusing on postmortem studies of psychosis. This special issue showcases the use of human brains postmortem to study psychiatric disorders, focusing on schizophrenia. The review articles highlight the benefits, achievements, problems, and perhaps most importantly, the future of postmortem research.

18 Jan 2011

Mithridion secures commitments of $1.25 million in new funding

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease, announces that it has secured commitments of $1.25 million in new funding.

11 Jan 2011

ACADIA raises $15 million through private placement

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a securities purchase agreement for a private placement financing with a select group of institutional investors, including New Enterprise Associates and Venrock.

10 Jan 2011

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

People suffering psychotic disorders 12 times more likely to commit suicide

People with psychotic disorders, such as schizophrenia or bipolar disorder, are 12 times more likely to commit suicide than average, according to research released today by King's Health Partners.

7 Dec 2010

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources. It also can have devastating health-related and social effects on people with the disease, their families and caregivers.

20 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Allen Institute releases new data and tools for exploring genes at work in human brain

The Allen Institute for Brain Science announced today its twentieth public data release, which includes new data and tools for exploring genes at work in the human brain. In addition to expanding and enhancing the Allen Human Brain Atlas, the Allen Institute launched two new human brain resources: the Ivy Glioblastoma Atlas Project and the NIMH Transcriptional Atlas of Human Brain Development.

3 Nov 2010

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

ACADIA Pharmaceuticals Inc. today announced that it has entered into an agreement with Biovail Laboratories International SRL ("BLS"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., pursuant to which ACADIA and BLS have agreed to conclude their previously established collaboration to develop and commercialize pimavanserin in the United States and Canada.

29 Oct 2010

Latuda tablets receive FDA approval for treatment of adults with schizophrenia

The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia.

29 Oct 2010

Common psychiatric drugs could slow dementia

Researchers say commonly used psychiatric drugs could be effective in slowing the progression of certain types of dementia. Dr John Kwok and colleagues from Neuroscience Research Australia have discovered a mutant gene that causes abnormal proteins build up in the brains of people with frontotemporal dementia, a disease that affects people in their 50s and 60s.

28 Oct 2010

Study observes interaction between HLA-C and ERAP1 genes in psoriasis

Genetic variants associated with increased susceptibility to psoriasis are reported in five papers published online this week in Nature Genetics. Psoriasis is a chronic and recurrent skin disease, and one of the most prevalent autoimmune diseases, with a global prevalence of 2-3%.

19 Oct 2010

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.

12 Oct 2010

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

6 Oct 2010

Researchers investigate ways to increase survival rate in patients with Parkinson's disease

New research shows how old people are when they first develop Parkinson's disease is one of many clues in how long they'll survive with the disease. The research is published in the October 5, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

5 Oct 2010

Psychosis News and Research

Further Reading

Cannabis use accelerates psychosis in the young: Study

Schizophrenia patients who consume antipsychotics appear to lose small amount of brain tissue

Study: Cannabis use appears to be linked with earlier onset of psychotic illness

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

Mithridion secures commitments of $1.25 million in new funding

ACADIA raises $15 million through private placement

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

People suffering psychotic disorders 12 times more likely to commit suicide

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Phase III study suggests CYCLOSET tablets improve glycemic control

Allen Institute releases new data and tools for exploring genes at work in human brain

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

Latuda tablets receive FDA approval for treatment of adults with schizophrenia

Common psychiatric drugs could slow dementia

Study observes interaction between HLA-C and ERAP1 genes in psoriasis

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Researchers investigate ways to increase survival rate in patients with Parkinson's disease

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News